Dexcom traded at $66.05 this Thursday March 26th, decreasing $0.79 or 1.18 percent since the previous trading session. Looking back, over the last four weeks, Dexcom lost 10.05 percent. Over the last 12 months, its price fell by 4.92 percent. Looking ahead, we forecast Dexcom to be priced at 64.82 by the end of this quarter and at 59.16 in one year, according to Trading Economics global macro models projections and analysts expectations.
Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.